RTGNRetinalGeniX Technologies Inc

About RetinalGeniX Technologies Inc (RTGN)

RetinalGeniX Technologies Inc (RTGN) is a Medical Devices company headquartered in Apollo Beach, FL, United States whose shares trade over-the-counter on the OTCQB tier.

RetinalGenix Technologies Inc. is an innovative ophthalmic research and development company seeking to revolutionize early disease detection and improve patient outcomes across multiple disease areas. Its proprietary High-Resolution Retinal Imaging and DNA/RNA/GPS™ Pharmaco-Genetic Mapping™ technologies are designed to help prevent blindness by detecting initial physiological changes that could indicate future ocular and systemic diseases affecting neurodegenerative, cardiovascular, vascular and metabolic systems, as well as diabetic conditions, Alzheimer’s disease and Parkinson’s disease. RetinalGenix is also developing therapeutic drugs for dry age-related macular degeneration (dry AMD) and Alzheimer’s disease/dementia. By integrating genetic screening, advanced imaging, and therapeutic development, RetinalGenix is positioned to become a leader in precision medicine.

Products and services

RetinalCam tm home monitoring and physician alert system (real-time) RetinalGeniX tm Imaging System( RIS) has now combined the company's DNA/GPS pharmco-mapping software app for patient profiling and systemic disease. The app and retinal images collect data for analysis.

RTGN key facts

Ticker symbol

RTGN

Market tier

OTCQB

Sector

Healthcare

Industry

Medical Devices

Headquarters

Apollo Beach, FL, United States

Country of incorporation

US

Year of incorporation

2017

Employees

1

Estimated market cap

$92.98M (as of May 13, 2025)

Shares outstanding

18,522,294

Reporting standard

U.S. Reporting: SEC Reporting

Audit status

Audited

Fiscal year end

12/31

RetinalGeniX Technologies Inc leadership

• Jerry Katzman MD — CEO, President

Explore more: Medical Devices stocks · Healthcare sector · OTCQB stocks · OTC stocks starting with R